Written by Dr. Ryan Kneessi, ND
This article is part of Supplement Science Explained, a Learning Hub collection on how common supplements work and what the research does and does not show.
Quick answer: Vitamin D3 is often sold with vitamin K2 because vitamin D helps the body absorb calcium, and vitamin K activates proteins that help bind calcium in bone and may help keep calcium from depositing in artery walls. That pairing is a reasonable theory, and it is a big part of why the combination became popular, but the clinical research on taking the two together is still smaller and less definitive than the marketing around it. Vitamin D3 generally raises blood 25-hydroxyvitamin D more effectively than vitamin D2 in a major meta-analysis, especially when given as a large intermittent dose. Vitamin K2, particularly the longer-chain form MK-7, stays in the blood longer than vitamin K1 and more fully carboxylates osteocalcin in a volunteer study, and it can interfere with warfarin. A very large trial of vitamin D3 alone did not reduce cancer or major cardiovascular events, so D3 is not a proven all-purpose shield. The right starting point is a 25-OH vitamin D blood test, a cautious dose, and a conversation with your clinician if you take a blood thinner or have a history of high calcium.
Taking a lot of supplements and not sure what's worth it?
Send me your list for a free supplement review. There is no cost and no appointment needed.
Key takeaways
Vitamin D, after it is converted to its active form, binds the vitamin D receptor and increases intestinal calcium absorption. Vitamin K is a cofactor for an enzyme that adds carbon dioxide to specific proteins, a step called carboxylation, which activates osteocalcin in bone and matrix Gla protein in tissues such as the vessel wall. The popular pairing is built on that calcium-handling logic.
A systematic review and meta-analysis of randomized trials found that vitamin D3 was more effective than vitamin D2 at raising serum 25-hydroxyvitamin D, with a clearer advantage when the vitamins were given as a bolus rather than as a daily dose. That is one reason D3, not D2, is the form most often used in combination products.
The VITAL trial assigned 25,871 adults to 2,000 international units of vitamin D3 or placebo for a median of 5.3 years and did not find a lower risk of invasive cancer or major cardiovascular events. That result matters, because it shows that a typical supplement dose of D3, by itself, did not deliver those widely hoped-for benefits in a generally vitamin D-replete older adult population.
Vitamin K, including K2, can antagonize warfarin and related anticoagulants. In a comparison of vitamin K1 and MK-7, researchers warned that 50 micrograms a day or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way. Anyone on warfarin should not start K2, or change their vitamin K intake, without the clinician who manages that medicine.
If you have looked at vitamin D supplements in the past few years, you have probably noticed that many of them now include vitamin K2. The combination has become popular among patients, wellness writers, and clinicians, and the question I hear is usually some version of “Is this necessary, or is it just a trend?” I think it is a fair question, because the pairing is based on real biochemistry, and because the evidence for taking the two together is not as settled as the popularity might suggest.
In this article I want to explain why D3 and K2 are so often joined, how vitamin D and vitamin K actually work, how D3 differs from D2 and how K2 differs from K1, including the MK-4 and MK-7 forms, and what human studies do and do not show. I will also cover 25-hydroxyvitamin D testing, the important interaction between vitamin K and warfarin, and the risk of taking too much vitamin D. I have already written more practical “how to take” and “who should consider” pieces on vitamin D and K2 together, vitamin D3, and vitamin K2 (MK-7). This article is meant to go deeper on the science and the limits of that science, not to replace those guides or to recommend a brand.
Why the combination became so popular
The short version of the sales pitch is this: vitamin D helps you absorb calcium, and vitamin K2 helps put that calcium in bones and keep it out of arteries. If you take vitamin D without vitamin K, the argument goes, you might raise calcium in the blood without giving the body the help it needs to steer that calcium to the right place. That story is easy to remember, and it sounds like a complete solution to two problems people worry about at the same time, weaker bones and stiffer arteries.
Parts of that story are grounded in real mechanisms, which I will describe below. Other parts are leaps. Vitamin D deficiency can contribute to poor bone mineralization, and vitamin K-dependent proteins do help bind calcium in bone and do appear in the vessel wall. Observational studies have linked higher dietary menaquinone intake with more favorable heart and calcification findings, and a few randomized trials of MK-7 in postmenopausal women have reported changes in bone and arterial-stiffness measures. What we do not have is a large, long trial showing that adding K2 to vitamin D3 clearly reduces fractures or heart attacks compared with vitamin D3 alone in a broad population. Popularity has moved faster than that kind of evidence, and I think readers deserve to hear that gap out loud.
How vitamin D works: the receptor, calcium absorption, and D3 versus D2
Vitamin D can come from sunlight, food, or a supplement. In the skin, ultraviolet B light converts a cholesterol derivative into vitamin D3. In the liver, vitamin D is converted to 25-hydroxyvitamin D, written as 25(OH)D, which is the form we measure in blood to judge status. In the kidney, and in some other tissues, 25(OH)D is converted to 1,25-dihydroxyvitamin D, the active hormone, also called calcitriol.
The active hormone binds the vitamin D receptor, or VDR. In a comprehensive review in Physiological Reviews, Sylvia Christakos and colleagues described how the liganded VDR partners with the retinoid X receptor and binds specific DNA sequences, turning target genes on or off, often from sites far from the start of the gene. One of the classical results of that signaling in the intestine is increased absorption of calcium, and also of phosphorus, from food. When vitamin D status is very low, the gut absorbs calcium poorly, blood calcium can fall, the parathyroid glands release more parathyroid hormone, and the body may pull calcium from bone to keep blood calcium in range. That is the well-established skeletal pathway, and it is the main reason vitamin D is considered essential for bone health. The same review discusses other proposed effects, including immune and cardiovascular ones, that are biologically interesting and still being tested in people.
Vitamin D comes in two main supplement forms. Vitamin D2, ergocalciferol, is made by irradiating plant or fungal sterols. Vitamin D3, cholecalciferol, is the form made in human skin and is also found in some animal foods. Chemically they differ only in the side chain, but they are not identical in how they raise blood levels. In a systematic review and meta-analysis in The American Journal of Clinical Nutrition, Laura Tripkovic and colleagues pooled randomized trials that had directly compared D2 and D3 in adults. They found that vitamin D3 had a significant and positive effect in raising serum 25(OH)D compared with vitamin D2. When they looked at dosing schedules, the advantage for D3 was clear when the vitamins were given as a bolus dose, and that advantage was not seen in the daily-dosing comparison. Their conclusion was that D3 is more efficacious at raising 25(OH)D and could become the preferred choice for supplementation, while more research was still needed across ages, sexes, and ethnicities. That finding helps explain why D3, rather than D2, is the form used in most D3 and K2 combinations.
The NIH Office of Dietary Supplements, following the Food and Nutrition Board, treats a serum 25(OH)D of 50 nanomoles per liter, or 20 nanograms per milliliter, or higher as generally adequate for bone and overall health in healthy people, and it associates levels below 30 nanomoles per liter, or 12 nanograms per milliliter, with deficiency, including a risk of rickets in children and osteomalacia in adults. Levels above 125 nanomoles per liter, or 50 nanograms per milliliter, are linked to potential adverse effects, particularly above 150 nanomoles per liter, or 60 nanograms per milliliter. The Recommended Dietary Allowance is 15 micrograms, or 600 international units, a day for most children and adults through age 70, and 20 micrograms, or 800 international units, a day thereafter, with the same 600-unit value in pregnancy and lactation. Those numbers are targets for intake, not automatic supplement doses, because sun exposure and baseline blood levels vary so much.
How vitamin K2 works: K1 versus K2, MK-4 and MK-7, and carboxylation
Vitamin K is the name for a family of related compounds. Vitamin K1, phylloquinone, is the main form in green leafy vegetables such as spinach, kale, and broccoli. Vitamin K2 refers to menaquinones, which have unsaturated side chains of different lengths and are named MK-4 through MK-13. According to the NIH vitamin K fact sheet, MK-4, MK-7, and MK-9 are the most studied menaquinones. K1 dominates in most diets that include leafy greens. K2 is found in smaller amounts in some fermented foods, such as natto, and in certain animal foods, and MK-4 can also be made in the body from vitamin K1.
The shared job of these forms is to act as a cofactor for the enzyme gamma-glutamyl carboxylase. That enzyme adds carbon dioxide to specific glutamate residues on vitamin K-dependent proteins, a step called carboxylation. Once carboxylated, those proteins can bind calcium. In the liver, this process activates clotting factors, which is why vitamin K was first known for coagulation and why the name comes from the German word for coagulation. Outside the liver, the same chemistry activates osteocalcin, a protein made by bone-forming cells, and matrix Gla protein, or MGP, which is found in cartilage and in the vessel wall. Carboxylated osteocalcin is involved in binding calcium in the bone matrix. Carboxylated MGP is one of the body’s natural inhibitors of soft-tissue calcification. This is the mechanistic heart of the D3 and K2 story: vitamin D can increase the calcium that enters the system and can also increase production of some of these proteins, and vitamin K is required to switch those proteins into their calcium-binding form.
The forms of vitamin K are not identical in the blood. In a study in Blood, Leon Schurgers and colleagues compared synthetic vitamin K1 with natto-derived MK-7 in healthy volunteers. Both were absorbed well, with peak serum concentrations at four hours. The striking difference was the very long half-life of MK-7, which produced much more stable serum levels and an accumulation of MK-7 to seven- to eight-fold higher levels during prolonged intake. MK-7 also induced more complete carboxylation of osteocalcin than K1 in that comparison. The authors warned hematologists that preparations supplying 50 micrograms a day or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way. MK-4 has a shorter side chain and a shorter presence in the blood than MK-7, and it is used in some studies at much higher milligram doses, especially in research from Japan. When people say “K2,” they may mean MK-7 at a low microgram dose, MK-4 at a very different dose, or a mixture. Those are not interchangeable products, even though they share the same basic carboxylation job.
The NIH lists Adequate Intakes for vitamin K of 120 micrograms a day for adult men and 90 micrograms a day for adult women, based mainly on the phylloquinone content of a typical diet, and it has not set a tolerable upper intake level because of insufficient data. There is no single agreed blood test that is considered a gold standard for vitamin K2 status. I discuss the marker questions, including inactive MGP, in my article on what a vitamin K2 status marker can and cannot show.
What the research shows, and what it does not
It helps to separate three questions that are often blended together. The first is whether vitamin D, by itself, prevents major diseases beyond treating deficiency. The second is whether dietary or supplemental K2 is associated with better bone or heart outcomes. The third is whether taking D3 and K2 together is proven to be better than taking D3 alone. The answers are not the same.
On the first question, the Vitamin D and Omega-3 Trial, or VITAL, is the most important recent study to know. JoAnn Manson and colleagues randomly assigned 25,871 men aged 50 and older and women aged 55 and older in the United States, including 5,106 Black participants, to 2,000 international units of vitamin D3 a day or placebo, in a two-by-two factorial design that also involved omega-3 fatty acids. After a median follow-up of 5.3 years, vitamin D did not lower the risk of invasive cancer of any type or the risk of major cardiovascular events, which meant a heart attack, stroke, or death from cardiovascular causes. There were 1,617 cancer diagnoses, 793 in the vitamin D group and 824 in the placebo group, for a hazard ratio of 0.96, with a 95 percent confidence interval of 0.88 to 1.06. A major cardiovascular event occurred in 805 participants, 396 with vitamin D and 409 with placebo, for a hazard ratio of 0.97, with a 95 percent confidence interval of 0.85 to 1.12. Death from cancer had a hazard ratio of 0.83, with a confidence interval that included 1.0. There was no excess of hypercalcemia or other adverse events at this dose. The trial does not say that vitamin D is unimportant for bones or for people who are truly deficient. It does say that 2,000 units a day did not prevent those primary cancer and cardiovascular outcomes in this large group of older adults.
On the second question, much of the enthusiasm for K2 comes from observational research and from a smaller number of trials. In the Rotterdam Study, Johanna Geleijnse and colleagues followed 4,807 adults who were free of myocardial infarction at baseline and looked at dietary phylloquinone and menaquinone. Higher menaquinone intake was associated with lower coronary heart disease mortality, lower all-cause mortality, and less severe aortic calcification, after adjustment for several risk factors and dietary variables. Compared with the lowest tertile, the upper tertile of menaquinone intake had a relative risk of 0.43 for coronary heart disease mortality, with a 95 percent confidence interval of 0.24 to 0.77, and an odds ratio of 0.48 for severe aortic calcification, with a 95 percent confidence interval of 0.32 to 0.71. Phylloquinone intake was not related to these outcomes. This was an observational study, so it cannot prove that menaquinone caused the difference. People who eat more K2-rich foods may differ in other ways as well.
A later cross-sectional study by Joline Beulens and colleagues in 564 postmenopausal women found that higher estimated menaquinone intake was associated with less coronary calcification, with a relative risk of 0.80 when the highest and lowest quartiles were compared, and a 95 percent confidence interval of 0.65 to 0.98. Phylloquinone intake was not associated with less calcification. Again, diet was estimated by questionnaire, and the design can show association, not cause.
Randomized trials of MK-7 give a more direct but still limited picture. In a three-year, double-blind trial, Marjo Knapen and colleagues assigned 244 healthy postmenopausal women to 180 micrograms of MK-7 a day or placebo. MK-7 improved vitamin K status, as measured by the ratio of uncarboxylated to carboxylated osteocalcin, and it decreased the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck, though not at the total hip. Bone strength indices at the femoral neck were also favorably affected. The same research group, in a related three-year trial in the same type of population, found that 180 micrograms of MK-7 a day improved some measures of arterial stiffness, with a larger effect in women who started with higher stiffness, and that it lowered circulating desphospho-uncarboxylated MGP by 50 percent compared with placebo. Those results are encouraging, and they fit the carboxylation mechanism. They were conducted in healthy postmenopausal women, not in a broad mixed-age population, and they used surrogate measures such as bone density, stiffness indices, and protein carboxylation, not a count of fractures or heart attacks. I would describe them as supportive, not as final proof that everyone who takes vitamin D should also take K2.
On the third question, the combination itself, the evidence is thinner than the product shelves suggest. Many D3 and K2 studies are small, use different forms and doses, or report laboratory markers rather than clinical events. It is biologically plausible that adequate vitamin K is important when vitamin D and calcium metabolism are being supported. It is not yet proven, at the level of large outcome trials, that a combined supplement prevents the diseases people most hope to avoid. I tell patients that correcting a low vitamin D level is a sound, evidence-aware step, that vitamin K from food is valuable, and that adding K2 is a judgment call to make with a clinician, especially if a blood thinner is in the picture. It should not be treated as a required companion in every case or as a substitute for the habits that actually build bone and protect arteries, including resistance exercise, not smoking, and a diet that includes leafy greens and other nutrient-dense foods. For a broader look at bone nutrition, see my article on bone health beyond calcium, and for the blood-test basics see the 25-OH vitamin D test.
Testing 25-hydroxyvitamin D
If you are wondering whether you need vitamin D at all, a blood test is more useful than a guess. The test to ask for is 25-hydroxyvitamin D, sometimes labeled 25-OH vitamin D or calcidiol. It reflects vitamin D from sun, food, and supplements and has a circulating half-life of about 15 days, according to the NIH. The active hormone, 1,25-dihydroxyvitamin D, is usually the wrong test for routine status, because it can stay in range even when stores are low.
How to interpret the number depends in part on which expert group you read. As noted above, the Food and Nutrition Board, as summarized by the NIH, treats 20 nanograms per milliliter as generally sufficient for most healthy people and flags deficiency risk below 12 nanograms per milliliter. Some professional societies have used higher targets, and laboratories sometimes mark a wider “insufficient” range. I would rather see a result, the season it was drawn, your skin coverage and time outdoors, your latitude, your body weight, and any conditions that affect absorption, than pick a dose from a bottle alone. Maryland winters, indoor work, darker skin, obesity, older age, and fat-malabsorption conditions all make lower levels more common. Once a supplement is started, repeating the test after a few months tells you whether the dose is doing what you intended, and it helps you avoid drifting into a high range.
Warfarin, too much vitamin D, and other safety issues
Vitamin K and warfarin are a clinically important pair. Warfarin and some related anticoagulants work by antagonizing vitamin K’s role in activating clotting factors. A sudden increase in vitamin K intake, including from a K2 supplement, can make the anticoagulant less effective and change the INR, the blood test used to monitor warfarin. The NIH vitamin K fact sheet states this interaction clearly. The Schurgers volunteer study, described above, went further and cautioned that 50 micrograms a day or more of MK-7 may be enough to matter. If you take warfarin, do not start or stop vitamin K2, and do not make large changes in your intake of vitamin K-rich foods, without the clinician who manages that medicine. Some newer anticoagulants work by different mechanisms and are not vitamin K antagonists, but you should still tell the prescribing clinician about any new supplement rather than assume it is irrelevant.
Vitamin D can also be taken to excess. Because it increases calcium absorption, very high intakes can raise blood calcium, a condition called hypercalcemia, which may cause nausea, confusion, kidney problems, and abnormal heart rhythm, and can lead to calcium deposits in soft tissue. The NIH notes potential adverse effects at high 25(OH)D concentrations, particularly above 60 nanograms per milliliter, and the Food and Nutrition Board set a tolerable upper intake level of 4,000 international units, or 100 micrograms, a day for adults. Some people take more than that under medical supervision with lab monitoring, and some people get into trouble by taking very large doses for months without testing. More is not a faster path to better health. If you use a combined D3 and K2 product, count the vitamin D from every source you take, including a multivitamin, a “bone” formula, and any high-dose weekly regimen.
Calcium supplements, thiazide diuretics, high-dose vitamin A, and granulomatous diseases can also affect calcium and vitamin D handling, and they are another reason to individualize rather than copy a dose from a social-media post. Pregnancy, nursing, kidney disease, a history of kidney stones, and a history of high blood calcium all warrant a conversation with a clinician before you start or raise a vitamin D supplement.
Frequently asked questions
Why is vitamin D3 with K2 so popular?
The combination is popular because it matches a clear biochemical story: vitamin D helps absorb calcium, and vitamin K activates proteins that help bind calcium in bone and may help limit calcification in soft tissue. That story is plausible, and some studies of K2 look encouraging, especially in postmenopausal women. The combination became a trend faster than large clinical trials could confirm that taking both together prevents fractures or heart disease better than taking vitamin D alone when it is needed.
Is vitamin D3 better than vitamin D2?
In a meta-analysis of randomized trials that compared the two forms head to head, vitamin D3 raised serum 25-hydroxyvitamin D more effectively than vitamin D2 overall, with a clearer benefit when the vitamins were given as a bolus dose. The advantage was not shown in the daily-dosing comparison in that analysis. D3 is the form made in human skin and is the one used in most combination products.
What is the difference between vitamin K1, MK-4, and MK-7?
Vitamin K1 comes mainly from leafy greens and is the main dietary form for most people. MK-4 and MK-7 are menaquinones, or vitamin K2. MK-7 stays in the blood longer than K1, accumulates with daily intake, and more fully carboxylated osteocalcin in a volunteer study. MK-4 is shorter-acting in the blood and has been studied at different, often much higher, doses. All of these forms support carboxylation, but they are not identical in how they behave in the body.
Do I need a blood test before I take vitamin D?
A 25-hydroxyvitamin D test is the most useful way to know whether you are low, adequate, or already high, and it is the test I prefer before a long course of supplementation and after a dose change. Some people with a clear lack of sun exposure in winter start a modest dose without a baseline test, but testing is the safer way to avoid both under- and overtreatment, especially if you are considering a higher dose.
Can I take vitamin K2 if I am on a blood thinner?
If the blood thinner is warfarin or another vitamin K antagonist, you should not start vitamin K2 unless the clinician who manages that medicine has approved it and has a plan to monitor your INR. Even 50 micrograms a day of MK-7 may be enough to matter. If you take a different type of anticoagulant, ask the prescribing clinician before you add K2, because supplement decisions still belong in that plan.
Can vitamin D be toxic?
Yes. Very high intakes can raise blood calcium and cause symptoms that range from nausea to kidney and heart-rhythm problems. The adult tolerable upper intake level set by the Food and Nutrition Board is 4,000 international units a day, and blood levels well above the usual sufficient range have been linked to potential harm. Toxicity is uncommon at ordinary dietary intakes and at modest supplement doses, and it is much more likely when high doses are taken for a long time without monitoring.
Vitamin D3 with K2 became popular for a reason that I respect: it tries to treat calcium as something that needs direction, not just absorption. The mechanisms are real, the form differences between D3 and D2 and between K1 and MK-7 are real, and some human studies are encouraging. The large outcome trial we do have for vitamin D3 alone did not show a reduction in cancer or major cardiovascular events, and the combination still needs better clinical evidence. A 25-OH vitamin D test, a modest evidence-aware plan, attention to warfarin if it applies, and a diet that includes vitamin K-rich foods remain a sturdier starting point than a trend alone.
Want a free supplement review?
Send me a list of the vitamins and supplements you take now, or a plan you built yourself or with ChatGPT, and I’ll look it over for free. There is no cost and no appointment, and you’ll hear back from me within about 48 hours.
Sources
This article is for educational purposes only and is not medical advice. It does not replace an individual evaluation. Talk with your healthcare provider before making changes to your diet, exercise, supplements, or medications, especially if you are pregnant or nursing, or are managing a health condition such as kidney disease, heart disease, or high blood pressure, or if you take prescription medicines.
Looking for practitioner-grade options?
The catalog carries third-party-tested, practitioner-grade supplements from brands Dr. Kneessi uses in practice.
See practitioner-grade options in the catalogNot sure what fits? Take the Supplement Quiz →


